NN

Naser Nazeer Patel

Active Director Designated Partner DIN 11228283
DIN 11228283 First appointment Aug 2025
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 2 active board seats
Total affiliations 2 Since Aug 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Naser Nazeer Patel

Data last updated:

Naser Nazeer Patel is a Designated Partner at Glomerulus Pharma Llp (since 2025) and Designated Partner at Nu Kidney Superspeciality Llp (since 2025).

DIN 11228283
Primary Designation Designated Partner
First Appointment 04 Aug 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner18 Aug 20252025Active
Designated Partner04 Aug 20252025Active

Board colleagues of Naser Nazeer Patel

Directorship timeline

Open interactive timeline →
Glomerulus Pharma Llp
Nu Kidney Superspeciality Llp
Premium access

Shareholding and investment profile for Naser Nazeer Patel

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Naser Nazeer Patel

Naser Nazeer Patel currently holds 2 directorships: Glomerulus Pharma Llp (Designated Partner, since 18 Aug 2025); Nu Kidney Superspeciality Llp (Designated Partner, since 04 Aug 2025).

Naser Nazeer Patel was first appointed on 04 Aug 2025 as Designated Partner at Nu Kidney Superspeciality Llp.

The current boards of Naser Nazeer Patel's companies include Bapu Ramrao Chege (Glomerulus Pharma Llp), Mahesh Shinde (Glomerulus Pharma Llp), Ramesh Kishanrao Jadhav (Glomerulus Pharma Llp).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available